ESGCT 2026 at a glance
ESGCT 2026 will spotlight emerging cell and gene therapy trends, from in vivo gene editing and CAR-T cell engineering to advanced delivery platforms and scalable manufacturing, with implications for clinical differentiation and biopharma competition.
📅 Build your schedule around the topics that matter most.
📥 Download the ESGCT_2026_Preview_by_LucidQuest
ESGCT 2026: Key Developments in Cell and Gene Therapy
In Vivo Gene Editing: YOLT-202 and BEAM-301
YOLT-202 and BEAM-301 will provide early clinical signals for base editing beyond ex vivo approaches.
These developments could help clarify the potential of in vivo gene editing strategies and their future clinical positioning.
In Vivo CAR-T Cell Therapy and Non-Viral Delivery Platforms
Lipid nanoparticle (LNP), lentiviral and virus-like particle (VLP) platforms could reshape how engineered T cells are generated inside patients.
Their development highlights competing approaches to in vivo CAR-T cell engineering and delivery.
Cell and Gene Therapy Manufacturing: AAV Production and Scalability
Adeno-associated virus (AAV) production, serum-free T-cell processing and non-viral delivery are emerging as critical competitive considerations.
Manufacturing reliability, scalability and platform selection may increasingly influence the development and commercialization of gene and cell therapies.
ESGCT 2026: Competitor and Industry Developments
Cytiva: LNP Delivery and In Vivo CAR-T Development
Cytiva’s LNP-enabled in vivo CAR-T and solid-tumour programmes will highlight evolving delivery strategies.
These developments reflect growing interest in delivery technologies that could support alternative approaches to cell engineering.
PlasmidFactory: Minicircle DNA and Virus-Free CAR-T Manufacturing
PlasmidFactory GmbH’s minicircle DNA and virus-free CAR-T manufacturing could offer alternatives to viral vector-dependent workflows.
Such approaches may influence manufacturing platform selection and process development.
Lonza and Sartorius: AAV Manufacturing and T-Cell Processing
Lonza and Sartorius will place platform reliability and scalability in focus through developments in AAV production, T-cell workflows and downstream processing.
These capabilities are increasingly relevant to manufacturing execution and the practical deployment of advanced therapies.
Emerging Gene and Cell Therapy Clinical Assets: ATA-200, ETX101 and AVB-406
ATA-200, ETX101 and AVB-406 will offer opportunities to assess safety, therapeutic activity and central nervous system (CNS) delivery.
The emerging evidence will be important for evaluating clinical differentiation and the potential of these investigational approaches.
Explore ESGCT 2026 Insights with LucidQuest
ESGCT 2026 will bring attention to how in vivo engineering, delivery technologies and manufacturing scalability are influencing the gene and cell therapy competitive landscape.
📅 Build your schedule around the sessions that matter most.
📥 Download the ESGCT_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
